Amedisys (AMED) Tops Q3 EPS by 18c, Raises FY Guidance

Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.95, $0.18 better than the analyst estimate of $0.77. Revenue for the quarter came in at $417.3 million versus the consensus estimate of $411.2 million.

GUIDANCE:

Amedisys sees FY2018 EPS of $3.54-$3.60, versus the consensus of $3.40. Amedisys sees FY2018 revenue of $1.65-1.67 billion, versus the consensus of $1.65 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
• ASP Isotopes holds first capital markets day, targets $300M EBITDA by 2031
• BMO Capital Reiterates Outperform Rating on NVIDIA (NVDA)